Journal profile · Hematology
Hematology
ISSN 1024-5332 · eISSN 1607-8454 · Taylor and Francis Ltd. · ENGLAND · Continuous publication · Founded 1996
Hematology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.01; fully open access; APC about USD 2,990; median 122 days to acceptance (101 articles, last 24 months); community-reported acceptance: 39%; 144 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Hematology is published by Taylor and Francis Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Acute Myeloid Leukemia Research, Hemoglobinopathies and Related Disorders and Hematopoietic Stem Cell Transplantation, together about 27.6% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Hematology is an international open access journal publishing original and review articles in the field of general hematology (haematology). Hematology is the Official Journal of the International Society of Hematology. The journal aims to bridge the interests and practices of those carrying out laboratory work and those working in patient care, emphasizing the clinical aspects of published material. Hematology also publishes interdisciplinary areas of research related to general hematology, including: Oncology Pathology Biology Clinical cancer research Epidemiology Thalassemias and leukemias The journal also accepts technical annotations covering current laboratory practice in general hematology; blood transfusion and clinical trials; and current clinical practice reviews of care and management. Hematology publishes research articles, review articles, systematic literature reviews, case reports, rapid communications, technical reports, registered reports, and letters to the editor. The journal operates a single-anonymized peer review policy.
From the journal's Aims & Scope
Research area (LetPub): Hematology
Editor-in-chief Adrian NewlandPublisher website
Editorial board by country: 1 in mainland China (about 3%); most named United States 13, United Kingdom 2, Japan 2, Italy 2, Türkiye 2 (33 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Acute Myeloid Leukemia ResearchMedicine12%
- Hemoglobinopathies and Related DisordersMedicine8.5%
- Hematopoietic Stem Cell TransplantationMedicine7.2%
- Blood groups and transfusionMedicine6.5%
- Platelet Disorders and TreatmentsMedicine6.1%
- Lymphoma Diagnosis and TreatmentMedicine5.6%
- Multiple Myeloma Research and TreatmentsMedicine5.5%
- Acute Lymphoblastic Leukemia researchMedicine5.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPubMedEmbaseCurrent ContentsPublisher website
Other: CML LEUKAEMIA AND LYMPHOMA
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.01LetPub ·
- Impact factor (publisher) 2025
- 2Publisher website ·
- 5-year impact factor (publisher) 2025
- 2Publisher website ·
- CiteScore 2026-06
- 3.2LetPub ·
- CiteScore (publisher) 2025
- 3.2Publisher website ·
- SJR 2026-06
- 0.6LetPub ·
- SJR (publisher) 2025
- 0.6Publisher website ·
- SNIP 2026-06
- 0.72LetPub ·
- SNIP (publisher) 2025
- 0.72Publisher website ·
- h-index
- 38LetPub ·
- h-index
- 63OpenAlex ·
- i10-index
- 1,117OpenAlex ·
- 2-year mean citedness
- 2.11OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 147LetPub ·
- Downloads per year (publisher)
- 987,000Publisher website ·
Articles by year OpenAlex count · 2,863 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 98 | 98 | 17 |
| 2025 | 144 | 144 | 233 |
| 2024 | 160 | 160 | 599 |
| 2023 | 195 | 195 | 1,165 |
| 2022 | 154 | 154 | 1,271 |
| 2021 | 137 | 137 | 1,574 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
122 daysMedian, submission to acceptance · P25–P75 88 days – 191 days
- Acceptance to online
- median 12 days (101 articles)
- Submission to online
- median 135 days
- Sample
- 101 articles with submission and acceptance dates (292 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- 39%LetPub ·
- Acceptance rate (publisher)
- 29%Publisher website ·
- Submission to first decision
- 19 daysPublisher website ·
- First decision after review
- 49 daysPublisher website ·
- Acceptance to publication
- 10 daysPublisher website ·
- Submission to publication (journal-reported)
- about 19 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | AUD 4,165 / EUR 2,875 / GBP 2,392 / USD 2,990 | Yes | CC BY, CC BY-NC | |
| OpenAlex | GBP 2,085 | — | — | |
| LetPub | USD 2,630 / GBP 2,100 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open access
Hematology is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readership of your article Make an impact and reach new readers, not just those with easy ac…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Continuous publication
- Founded
- 1996
- ISSN
- 1024-5332
- Electronic ISSN
- 1607-8454
- Society / sponsor
- International Society of Hematology
- Latest issue on the website
- Volume 31, Issue 1 (2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Hematology
What CAS zone is Hematology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Hematology is in Zone 4 of Medicine, and in Zone 4 of the minor category Hematology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Hematology?
The latest impact factor listed by LetPub is 2.01; CiteScore 3.2, h-index 63.
How long does peer review take at Hematology?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 122 days (interquartile range 88–191 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “39%”; the journal's website gives an acceptance rate of 29%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Hematology based?
Of the 33 board members whose country the journal's board page names, 1 (about 3%) are in mainland China; the countries named most often are United States (13), United Kingdom (2) and Japan (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Hematology?
According to LetPub and DOAJ records, Hematology is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, PubMed, Embase and Current Contents; that list has not been checked against each database.
Is Hematology open access, and what is the APC?
Hematology is a fully open-access journal. APC about USD 2,990.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .